OP06 Multiomic interrogation of the epithelium in active Ulcerative Colitis reveals dysregulated myeloid cells associated with non-response to anti-Tumour Necrosis Factor therapy.

Jha , D.(1)*;Al-Taie , Z.(2);Krek , A.(3);Eshghi , S.(4);Tankelevich , M.(1);Meringer , H.(5);Cossarini , F.(6);Canales-Herrerias , P.(1);Livanos , A.E.(1); Polydorides , A.D.(7);Martin , J.(8);Ko , H.M.(9);McBride , J.(4);Hackney , J.(10);Colombel , J.F.(1);Argmann , C.(11);Suarez-Farinas , M.(11);Petralia , F.(11);Mehandru , S.(1);

(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York City, United States;(2)Icahn School of Medicine at Mount Sinai, Genetics and Genomic Sciences- Population Health Science and Policy, New York City, United States;(3)Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences-, New York City, United States;(4)Genentech Inc, OMNI Biomarker Development, San Francisco, United States;(5)Assuta Ashdod Medical Center, Department of Gastroenterology and Liver diseases, Ashdod, Israel;(6)Icahn School of Medicine at Mount Sinai, Infectious Diseases, New York City, United States;(7)Icahn School of Medicine at Mount Sinai, Pathology, New York City, United States;(8)Université de Nantes, Centre de Recherche en Transplantation et Immunologie, Nantes, France;(9)Columbia University, Pathology, New York City, United States;(10)Genentech Inc, OMNI Bioinformatics, San Francisco, United States;(11)Icahn School of Medicine at Mount Sinai, Genetics and Genomic Sciences, New York City, United States;

Background

While the majority of Ulcerative Colitis (UC)-related mucosal studies have focused on whole intestinal tissues or the lamina propria (LP), epithelial compartment (EC)-specific studies are largely lacking. Here, we have defined EC-associated molecular and cellular dynamics during inflammation and studied their response to anti-tumor necrosis factor inhibitor (TNFi) therapy.

Methods

EC-focused analyses that included total RNA sequencing (RNAseq), single-cell (sc) RNAseq,  spatial transcriptomics (ST), microscopy and flow cytometry (FC) were performed in a cohort of UC patients (n=103) and healthy controls (HC, n=116); Primary Cohort (PC). Inflammation-associated signatures were validated in an internal validation cohort (VC-1; UC, n= 401; HC, n = 243). Additionally, 3 distinct validation cohorts (VC-2a, n=23; VC-3b, n=48; VC-4c, n=214) were used to determine cellular and molecular phenotypes that were associated with TNFi-treatment response.

a. Gut, 2018; PMID-27802155

b. Am J Gastroenterol., 2011; PMID- 21448149

c. Lancet Gastroenterol Hepatol., 2022; PMID: 34798036

Results

Total RNAseq and scRNA seq analyses and FC revealed distinct immune perturbations in the EC of patients with UC, including a major increase in neutrophils, monocyte-macrophages (MoMac) and inflammatory macrophages, while EC-resident, homeostatic gd T cells were significantly reduced (Fig 1A, B). ST identified significantly reduced frequencies of mature epithelial subtypes in UC and significantly increased co-localization between multiple cell types, including epithelial cells and myeloid cells (Fig 1C), that was confirmed by microscopy (Fig 1D).

A signature of 255 EC inflammation-associated genes was derived that reversed with TNFi. This included treatment associated reduced expression of genes such as CSF3R, FCGR3B, MZB1, PDPN, TREM, FPR2 with a concomitant increased expression of genes like BEST4, CA2, SLC16A1, UGT1A10 (Fig 1E). Interrogation of UC-associated inflammatory cell types within VC-2, VC-3, and VC-4 demonstrated that reduction in neutrophils, MoMac, macrophages, DCs and plasma cells and an increase in epithelial cells was associated with TNFi response. Furthermore, early (W8-W10) reductions in myeloid cell- and plasma cell-associated genes was associated with TNFi response (Fig 1F, G).

Conclusion

Detailed multiomic characterization of the EC in UC reveals myeloid cell-, plasma cell- and epithelial cell-associated modules that are associated with non-response to TNFi and charts a course to define rational drug sequencing and combinations in UC.